GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

Gilead (GILD) beat Q2 revenue estimates as HIV sales drove growth, but reported a loss due to acquisition charges. Management reiterated higher HIV guidance and cited pipeline progress, supporting continued momentum despite the one-off costs. Overall, the earnings beat and improved outlook are the key positives for investors.

Analysis

Gilead (GILD) beat Q2 revenue estimates as HIV sales drove growth, but reported a loss due to acquisition charges. Management reiterated higher HIV guidance and cited pipeline progress, supporting continued momentum despite the one-off costs. Overall, the earnings beat and improved outlook are the key positives for investors.